NEWS
Discover recent news, press, publications & congress and industry news below.
For access to a press kit, please contact a member of the media team at info@anthostherapeutics.com.
First-Ever Cost-Effectiveness Analysis of a Factor XI Inhibitor
May 6, 2024 | NEW RELEASES
First-Ever Cost-Effectiveness Analysis of a Factor XI Inhibitor Demonstrates that Abelacimab, if Approved, Could Offer Significant Cost Savings as Compared to a Current Standard of Care Anticoagulant NEWS PROVIDED BY Anthos Therapeutics May 6, 2024 10:32 ET Treatment...
Anthos Therapeutics Announces Appointment of Bill Meury as CEO
Apr 22, 2024 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics April 22, 2024 11:00 ET CAMBRIDGE, Mass., – April 22, 2024 – Anthos Therapeutics, Inc. (Anthos), is a clinical-stage company developing innovative therapies for cardiovascular diseases, founded by Blackstone Life Sciences (BXLS),...
Anthos Therapeutics’ Novel Dual Acting Factor XI / XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation
Nov 12, 2023 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics → November 12, 2023 08:15 ET Secondary Endpoints Also Showed a Highly Significant 74% Reduction in Major Bleeding and a 93% Reduction in Gastrointestinal (GI) Bleeding with Abelacimab These Results Triggered the Data Monitoring...
Study Confirming Overwhelming Reduction in Bleeding of the Dual-Acting Factor XI/XIa Inhibitor Abelacimab as Compared to Rivaroxaban Selected as Late-Breaker Oral Presentation at the American Heart Association Scientific Sessions
Sep 26, 2023 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics September 26, 2023 07:00 ET Study Participants May Transition from the Rivaroxaban Arm to Abelacimab in an Extension Study CAMBRIDGE, Mass., September 26, 2023 (BUSINESS WIRE) – Anthos Therapeutics, Inc., a clinical stage...
Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC (Direct Oral Anticoagulant)
Sep 18, 2023 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics September 18, 2023 06:00 ET Abelacimab, a Dual-Acting Factor XI / XIa Inhibitor, Demonstrated an Unprecedented Reduction in Bleeding in the Largest and Longest Head-to-Head Study Comparing a Factor XI Inhibitor to a DOAC Abelacimab...
Anthos Therapeutics Supported Global Survey of 3000+ Patients Prescribed Anticoagulants Detailing Impact of Patient-Relevant Bleeding (PRB) Presented at ISTH 2023
Jun 26, 2023 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics June 26, 2023, 02:00 ET Patient-Centric Survey Conducted in Collaboration with StopAfib.org and the National Blood Clot Alliance Findings Suggest “Patient-Relevant Bleeding” More Accurate Than Current Terminology, Capturing...
Regulatory Authorities in China and Japan Approve Clinical Trials for Anthos Therapeutics’ Dual-Acting Factor XI/XIa Inhibitor Abelacimab
Jun 8, 2023 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics June 08, 2023 11:10 ET Fewer than 26% of Chinese Patients with Atrial Fibrillation are Prescribed an Anticoagulant, while in Japan Almost One-Third of Patients are Undertreated Approximately 63% of Cancer Patients in China...
New Assessment Scale to Measure Adherence to Oral Anticoagulants Based on Impact of Patient Relevant Bleeding in Atrial Fibrillation Presented at ISPOR 2023
May 9, 2023 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics May 09, 2023 09:45 ET Anticoagulant Bleeding Burden Adherence Confidence Assessment Scale [ABBA-CAS] Created to Better Address an Important Treatment Gap in the Management of Atrial Fibrillation (AF) and Bring Patient Issues to the...
Anthos Therapeutics to Present Four Posters at ISPOR 2023
May 5, 2023 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics May 05, 2023 08:00 ET Additional presentation spotlights GARDENIA registry design in patients with atrial fibrillation and atrial flutter Early Cost-Effectiveness Modeling for Patients with Atrial Fibrillation and Cancer Associated...
First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current Anticoagulants
Jan 3, 2023 | NEW RELEASES
NEWS PROVIDED BY Anthos Therapeutics Jan 3, 2023, 08:00 ET FDA Fast-Track designation was granted to investigate abelacimab for the prevention of stroke and systemic embolism in patients with atrial fibrillation LILAC-TIMI 76 trial is the third Phase 3 study with...